| In-home Lab Connection Inc | |
| 2626 East 82nd Street, Suite 305, Bloomington, Minnesota 55425 | |
| (952) 842-9000 | |
| Name | In-home Lab Connection Inc |
|---|---|
| Location | 2626 East 82nd Street, Suite 305, Bloomington, Minnesota |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 248120 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 55024, 55044, 55103, 55108, 55112, 55118, 55124, 55125, 55318, 55337, 55344, 55345, 55404, 55405, 55406, 55411, 55412, 55413, 55414, 55416, 55418, 55419, 55421, 55422, 55427, 55428, 55429, 55430, 55432, 55433, 55434, 55435, 55436, 55437, 55441, 55442, 55443, 55448 |
| NPI Number | 1013026707 |
| Organization Name | ALL HOME HEALTH INCORPORATED |
| Address | 2626 E 82nd St, Suite 180, Bloomington, MN 55425 |
| Phone Number | 952-814-7400 |
News Archive
Alma Lasers Ltd., a global leader in aesthetic laser, light-based, and radiofrequency systems, announces important developments in its patent dispute with Lumenis Ltd., which is being litigated in the United States District Court in Chicago, IL. Alma reports that: (1) the U.S. Patent and Trademark Office in Alexandria VA ("PTO") has decided to reexamine all seven of Lumenis's patents that are at issue in the litigation, and (2) the Court has stayed the litigation, pending reexamination of the patents.
MYC is an oncogenic member of the basic helix-loop-helix-leucine zipper transcription factor family. In its monomeric form, MYC's tertiary structure is intrinsically disordered and the protein is transcriptionally inactive.
The Center for Strategic & International Studies (CSIS) on Monday "hosted the public launch of the new USAID Global Health Strategy to support implementation of the Global Health Initiative," according to its website.
Bioconnect Systems, Inc. announced today that data from the Company's first clinical study will be presented this week at the ASN Meeting in San Diego. Bioconnect's implant platform, the Optiflow™, enhances a surgeon's ability to create precise vascular connections.
Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/060,641, which covers the composition and use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate.
› Verified 1 days ago
| NPI Number | 1013386408 |
| Organization Name | WILKEN & ASSOCIATES, LLC |
| Doing Business As | TOUCHING HEARTS AT HOME |
| Address | 2626 E 82nd St, 145, Bloomington, MN 55425 |
| Phone Number | 952-888-0321 |
News Archive
Alma Lasers Ltd., a global leader in aesthetic laser, light-based, and radiofrequency systems, announces important developments in its patent dispute with Lumenis Ltd., which is being litigated in the United States District Court in Chicago, IL. Alma reports that: (1) the U.S. Patent and Trademark Office in Alexandria VA ("PTO") has decided to reexamine all seven of Lumenis's patents that are at issue in the litigation, and (2) the Court has stayed the litigation, pending reexamination of the patents.
MYC is an oncogenic member of the basic helix-loop-helix-leucine zipper transcription factor family. In its monomeric form, MYC's tertiary structure is intrinsically disordered and the protein is transcriptionally inactive.
The Center for Strategic & International Studies (CSIS) on Monday "hosted the public launch of the new USAID Global Health Strategy to support implementation of the Global Health Initiative," according to its website.
Bioconnect Systems, Inc. announced today that data from the Company's first clinical study will be presented this week at the ASN Meeting in San Diego. Bioconnect's implant platform, the Optiflow™, enhances a surgeon's ability to create precise vascular connections.
Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/060,641, which covers the composition and use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate.
› Verified 1 days ago
| NPI Number | 1134409667 |
| Organization Name | HOME LAB PARTNERS INC |
| Address | 2626 E 82nd St, Suite 101, Bloomington, MN 55425 |
| Phone Number | 952-842-9000 |
News Archive
Alma Lasers Ltd., a global leader in aesthetic laser, light-based, and radiofrequency systems, announces important developments in its patent dispute with Lumenis Ltd., which is being litigated in the United States District Court in Chicago, IL. Alma reports that: (1) the U.S. Patent and Trademark Office in Alexandria VA ("PTO") has decided to reexamine all seven of Lumenis's patents that are at issue in the litigation, and (2) the Court has stayed the litigation, pending reexamination of the patents.
MYC is an oncogenic member of the basic helix-loop-helix-leucine zipper transcription factor family. In its monomeric form, MYC's tertiary structure is intrinsically disordered and the protein is transcriptionally inactive.
The Center for Strategic & International Studies (CSIS) on Monday "hosted the public launch of the new USAID Global Health Strategy to support implementation of the Global Health Initiative," according to its website.
Bioconnect Systems, Inc. announced today that data from the Company's first clinical study will be presented this week at the ASN Meeting in San Diego. Bioconnect's implant platform, the Optiflow™, enhances a surgeon's ability to create precise vascular connections.
Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/060,641, which covers the composition and use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate.
› Verified 1 days ago
| NPI Number | 1215046305 |
| Organization Name | IN-HOME LAB CONNECTION INC. |
| Address | 4064 Olivine Dr, Eagan, MN 55122 |
| Phone Number | 952-842-9000 |
News Archive
Alma Lasers Ltd., a global leader in aesthetic laser, light-based, and radiofrequency systems, announces important developments in its patent dispute with Lumenis Ltd., which is being litigated in the United States District Court in Chicago, IL. Alma reports that: (1) the U.S. Patent and Trademark Office in Alexandria VA ("PTO") has decided to reexamine all seven of Lumenis's patents that are at issue in the litigation, and (2) the Court has stayed the litigation, pending reexamination of the patents.
MYC is an oncogenic member of the basic helix-loop-helix-leucine zipper transcription factor family. In its monomeric form, MYC's tertiary structure is intrinsically disordered and the protein is transcriptionally inactive.
The Center for Strategic & International Studies (CSIS) on Monday "hosted the public launch of the new USAID Global Health Strategy to support implementation of the Global Health Initiative," according to its website.
Bioconnect Systems, Inc. announced today that data from the Company's first clinical study will be presented this week at the ASN Meeting in San Diego. Bioconnect's implant platform, the Optiflow™, enhances a surgeon's ability to create precise vascular connections.
Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/060,641, which covers the composition and use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate.
› Verified 1 days ago
| NPI Number | 1578525317 |
| Organization Name | AMERIMED HOME CARE, INC. |
| Doing Business As | FREEDOM HOME HEALTH AGENCY, INC. |
| Address | 2626 E 82nd St, Suite 260, Bloomington, MN 55425 |
| Phone Number | 952-854-9071 |
News Archive
Alma Lasers Ltd., a global leader in aesthetic laser, light-based, and radiofrequency systems, announces important developments in its patent dispute with Lumenis Ltd., which is being litigated in the United States District Court in Chicago, IL. Alma reports that: (1) the U.S. Patent and Trademark Office in Alexandria VA ("PTO") has decided to reexamine all seven of Lumenis's patents that are at issue in the litigation, and (2) the Court has stayed the litigation, pending reexamination of the patents.
MYC is an oncogenic member of the basic helix-loop-helix-leucine zipper transcription factor family. In its monomeric form, MYC's tertiary structure is intrinsically disordered and the protein is transcriptionally inactive.
The Center for Strategic & International Studies (CSIS) on Monday "hosted the public launch of the new USAID Global Health Strategy to support implementation of the Global Health Initiative," according to its website.
Bioconnect Systems, Inc. announced today that data from the Company's first clinical study will be presented this week at the ASN Meeting in San Diego. Bioconnect's implant platform, the Optiflow™, enhances a surgeon's ability to create precise vascular connections.
Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/060,641, which covers the composition and use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate.
› Verified 1 days ago
| NPI Number | 1841252681 |
| Organization Name | FREEDOM HEALTH CARE, INC. |
| Address | 2626 E 82nd St, Suite 260, Bloomington, MN 55425 |
| Phone Number | 952-854-6889 |
News Archive
Alma Lasers Ltd., a global leader in aesthetic laser, light-based, and radiofrequency systems, announces important developments in its patent dispute with Lumenis Ltd., which is being litigated in the United States District Court in Chicago, IL. Alma reports that: (1) the U.S. Patent and Trademark Office in Alexandria VA ("PTO") has decided to reexamine all seven of Lumenis's patents that are at issue in the litigation, and (2) the Court has stayed the litigation, pending reexamination of the patents.
MYC is an oncogenic member of the basic helix-loop-helix-leucine zipper transcription factor family. In its monomeric form, MYC's tertiary structure is intrinsically disordered and the protein is transcriptionally inactive.
The Center for Strategic & International Studies (CSIS) on Monday "hosted the public launch of the new USAID Global Health Strategy to support implementation of the Global Health Initiative," according to its website.
Bioconnect Systems, Inc. announced today that data from the Company's first clinical study will be presented this week at the ASN Meeting in San Diego. Bioconnect's implant platform, the Optiflow™, enhances a surgeon's ability to create precise vascular connections.
Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/060,641, which covers the composition and use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate.
› Verified 1 days ago
| NPI Number | 1902915606 |
| Organization Name | HOME FREE INCORPORATED |
| Address | 8100 26th Ave S, Suite 165, Bloomington, MN 55425 |
| Phone Number | 952-814-7400 |
News Archive
Alma Lasers Ltd., a global leader in aesthetic laser, light-based, and radiofrequency systems, announces important developments in its patent dispute with Lumenis Ltd., which is being litigated in the United States District Court in Chicago, IL. Alma reports that: (1) the U.S. Patent and Trademark Office in Alexandria VA ("PTO") has decided to reexamine all seven of Lumenis's patents that are at issue in the litigation, and (2) the Court has stayed the litigation, pending reexamination of the patents.
MYC is an oncogenic member of the basic helix-loop-helix-leucine zipper transcription factor family. In its monomeric form, MYC's tertiary structure is intrinsically disordered and the protein is transcriptionally inactive.
The Center for Strategic & International Studies (CSIS) on Monday "hosted the public launch of the new USAID Global Health Strategy to support implementation of the Global Health Initiative," according to its website.
Bioconnect Systems, Inc. announced today that data from the Company's first clinical study will be presented this week at the ASN Meeting in San Diego. Bioconnect's implant platform, the Optiflow™, enhances a surgeon's ability to create precise vascular connections.
Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/060,641, which covers the composition and use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate.
› Verified 1 days ago
| Quality Rating: |
News Archive
Alma Lasers Ltd., a global leader in aesthetic laser, light-based, and radiofrequency systems, announces important developments in its patent dispute with Lumenis Ltd., which is being litigated in the United States District Court in Chicago, IL. Alma reports that: (1) the U.S. Patent and Trademark Office in Alexandria VA ("PTO") has decided to reexamine all seven of Lumenis's patents that are at issue in the litigation, and (2) the Court has stayed the litigation, pending reexamination of the patents.
MYC is an oncogenic member of the basic helix-loop-helix-leucine zipper transcription factor family. In its monomeric form, MYC's tertiary structure is intrinsically disordered and the protein is transcriptionally inactive.
The Center for Strategic & International Studies (CSIS) on Monday "hosted the public launch of the new USAID Global Health Strategy to support implementation of the Global Health Initiative," according to its website.
Bioconnect Systems, Inc. announced today that data from the Company's first clinical study will be presented this week at the ASN Meeting in San Diego. Bioconnect's implant platform, the Optiflow™, enhances a surgeon's ability to create precise vascular connections.
Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/060,641, which covers the composition and use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate.
› Verified 1 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 61.3 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 98.7 | 98.6 |
| How often the home health team checked patients’ risk of falling | 98.4 | 99.6 |
| How often the home health team checked patients for depression | 100 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 34.8 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 65.7 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 100 | 96.4 |
News Archive
Alma Lasers Ltd., a global leader in aesthetic laser, light-based, and radiofrequency systems, announces important developments in its patent dispute with Lumenis Ltd., which is being litigated in the United States District Court in Chicago, IL. Alma reports that: (1) the U.S. Patent and Trademark Office in Alexandria VA ("PTO") has decided to reexamine all seven of Lumenis's patents that are at issue in the litigation, and (2) the Court has stayed the litigation, pending reexamination of the patents.
MYC is an oncogenic member of the basic helix-loop-helix-leucine zipper transcription factor family. In its monomeric form, MYC's tertiary structure is intrinsically disordered and the protein is transcriptionally inactive.
The Center for Strategic & International Studies (CSIS) on Monday "hosted the public launch of the new USAID Global Health Strategy to support implementation of the Global Health Initiative," according to its website.
Bioconnect Systems, Inc. announced today that data from the Company's first clinical study will be presented this week at the ASN Meeting in San Diego. Bioconnect's implant platform, the Optiflow™, enhances a surgeon's ability to create precise vascular connections.
Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/060,641, which covers the composition and use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate.
› Verified 1 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 41.1 | 79.6 |
| How often patients got better at getting in and out of bed | 54.1 | 81.1 |
| How often patients got better at bathing | 34.1 | 82.3 |
| How often patients’ breathing improved | 27.4 | 82.8 |
| How often patients’ wounds improved or healed after an operation | - | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 36.2 | 75 |
| How often home health patients had to be admitted to the hospital | - | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | - | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 76.9 | 94 |
News Archive
Alma Lasers Ltd., a global leader in aesthetic laser, light-based, and radiofrequency systems, announces important developments in its patent dispute with Lumenis Ltd., which is being litigated in the United States District Court in Chicago, IL. Alma reports that: (1) the U.S. Patent and Trademark Office in Alexandria VA ("PTO") has decided to reexamine all seven of Lumenis's patents that are at issue in the litigation, and (2) the Court has stayed the litigation, pending reexamination of the patents.
MYC is an oncogenic member of the basic helix-loop-helix-leucine zipper transcription factor family. In its monomeric form, MYC's tertiary structure is intrinsically disordered and the protein is transcriptionally inactive.
The Center for Strategic & International Studies (CSIS) on Monday "hosted the public launch of the new USAID Global Health Strategy to support implementation of the Global Health Initiative," according to its website.
Bioconnect Systems, Inc. announced today that data from the Company's first clinical study will be presented this week at the ASN Meeting in San Diego. Bioconnect's implant platform, the Optiflow™, enhances a surgeon's ability to create precise vascular connections.
Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/060,641, which covers the composition and use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate.
› Verified 1 days ago
News Archive
Alma Lasers Ltd., a global leader in aesthetic laser, light-based, and radiofrequency systems, announces important developments in its patent dispute with Lumenis Ltd., which is being litigated in the United States District Court in Chicago, IL. Alma reports that: (1) the U.S. Patent and Trademark Office in Alexandria VA ("PTO") has decided to reexamine all seven of Lumenis's patents that are at issue in the litigation, and (2) the Court has stayed the litigation, pending reexamination of the patents.
MYC is an oncogenic member of the basic helix-loop-helix-leucine zipper transcription factor family. In its monomeric form, MYC's tertiary structure is intrinsically disordered and the protein is transcriptionally inactive.
The Center for Strategic & International Studies (CSIS) on Monday "hosted the public launch of the new USAID Global Health Strategy to support implementation of the Global Health Initiative," according to its website.
Bioconnect Systems, Inc. announced today that data from the Company's first clinical study will be presented this week at the ASN Meeting in San Diego. Bioconnect's implant platform, the Optiflow™, enhances a surgeon's ability to create precise vascular connections.
Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/060,641, which covers the composition and use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate.
› Verified 1 days ago
In-home Lab Connection Inc Location: 2626 East 82nd Street, Suite 305, Bloomington, Minnesota 55425 Ratings: Phone: (952) 842-9000 | |
Senior Home Health Care Llc Location: 7800 Metro Parkway Suite 100, Bloomington, Minnesota 55425 Ratings: Phone: (612) 298-8180 |